Washington: In a breakthrough discovery, researchers have found a compound that accelerates wound healing in diabetes patients, which can help to make new treatment strategies.


COMMERCIAL BREAK
SCROLL TO CONTINUE READING

University of Notre Dame researchers have reported the discovery of a MMP-9 inhibitor referred to as ND-336 which can help in healing diabetic wounds.


The researchers had previously believed that two enzymes called matrix metalloproteinases (MMPs), MMP-8 and MMP-9, might play a role in the body's response to wound healing in diabetic mice.


The researchers used the MMP-9 inhibitor referred to as ND-322, which accelerated wound healing in diabetic mice.


Lead researcher Mayland Chang said that ND-336 was a six-fold more potent inhibitor than ND-322 and has 50-fold selectivity towards inhibition of MMP-9 than MMP-8, adding that ND-322 has three-fold selectivity towards inhibition of MMP-9 compared to MMP-8.


Researchers compared the efficacy of ND-336 versus ND-322 and found that wounds treated with ND-336 healed significantly faster than those treated with ND-322 because of the better selectivity of ND-336 than ND-322 for inhibition of MMP-9 over MMP-8.


In the study, they applied the enzyme MMP-8 to wounds of diabetic mice and found accelerated wound healing and also combined the MMP-9 inhibitor ND-336 and the enzyme MMP-8 and found further acceleration of diabetic wound healing.


Chang said that the compound ND-336 had potential as a therapeutic to accelerate or facilitate wound healing in diabetic patients.


The study is published in the Journal Proceedings of the National Academy of Sciences.